Similar articles for PMID: 30587289

Year	Number of Results
1977	1
1980	1
1982	1
1983	4
1985	6
1986	11
1988	4
1989	2
1990	3
1991	4
1992	4
1993	5
1994	1
1995	5
1996	2
1997	4
1998	1
2001	2
2002	3
2004	2
2005	1
2006	1
2008	1
2009	1
2010	1
2012	1
2015	1
2016	2
2017	1
2018	4
2019	6
2021	1
2024	0

1

Cefiderocol for treatment of complicated urinary tract infections.

Wagenlehner FME, Naber KG. Wagenlehner FME, et al. Lancet Infect Dis. 2019 Jan;19(1):22-23. doi: 10.1016/S1473-3099(18)30722-9. Lancet Infect Dis. 2019. PMID: 30587289 No abstract available.

2

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.

Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke P, Nagata TD. Portsmouth S, et al. Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509675 Clinical Trial.

3

Cefiderocol for treatment of complicated urinary tract infections.

Portsmouth S, Echols R, Den Nagata T. Portsmouth S, et al. Lancet Infect Dis. 2019 Jan;19(1):23-24. doi: 10.1016/S1473-3099(18)30721-7. Lancet Infect Dis. 2019. PMID: 30587290 No abstract available.

4

Cefiderocol for treatment of complicated urinary tract infections - Author's reply.

Huttner A. Huttner A. Lancet Infect Dis. 2019 Jan;19(1):24-25. doi: 10.1016/S1473-3099(18)30728-X. Lancet Infect Dis. 2019. PMID: 30587291 No abstract available.

5

Cefiderocol in context.

Huttner A. Huttner A. Lancet Infect Dis. 2018 Dec;18(12):1290-1291. doi: 10.1016/S1473-3099(18)30615-7. Epub 2018 Oct 25. Lancet Infect Dis. 2018. PMID: 30509674 No abstract available.

6

Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.

Zhanel GG, Golden AR, Zelenitsky S, Wiebe K, Lawrence CK, Adam HJ, Idowu T, Domalaon R, Schweizer F, Zhanel MA, Lagacé-Wiens PRS, Walkty AJ, Noreddin A, Lynch Iii JP, Karlowsky JA. Zhanel GG, et al. Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2. Drugs. 2019. PMID: 30712199 Review.

7

[Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].

Naber KG, Adam D, Bauernfeind A, Hönig E. Naber KG, et al. Infection. 1986;14 Suppl 2:S122-9. doi: 10.1007/BF01647496. Infection. 1986. PMID: 2428754 German.

8

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

Sims M, Mariyanovski V, McLeroth P, Akers W, Lee YC, Brown ML, Du J, Pedley A, Kartsonis NA, Paschke A. Sims M, et al. J Antimicrob Chemother. 2017 Sep 1;72(9):2616-2626. doi: 10.1093/jac/dkx139. J Antimicrob Chemother. 2017. PMID: 28575389 Clinical Trial.

9

Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections.

Naber KG, Savov O, Salmen HC. Naber KG, et al. Int J Antimicrob Agents. 2002 Feb;19(2):95-103. doi: 10.1016/s0924-8579(01)00481-2. Int J Antimicrob Agents. 2002. PMID: 11850161 Clinical Trial.

10

[Imipenem/cilastatin in surgical intensive medicine].

Wenk H, Schier H, Hollandt H, Valesky A. Wenk H, et al. Infection. 1986;14 Suppl 2:S171-5. doi: 10.1007/BF01647504. Infection. 1986. PMID: 3759252 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

87 results

Results by year